Bausch Health Cos (BHC) to Release Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) is expected to be announcing its Q4 2025 results after the market closes on Wednesday, February 18th. Analysts expect Bausch Health Cos to post earnings of $1.22 per share and revenue of $2.7093 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 18, 2026 at 5:00 PM ET.

Bausch Health Cos Stock Performance

NYSE BHC opened at $6.16 on Wednesday. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 57.48. The firm’s fifty day moving average price is $6.77 and its two-hundred day moving average price is $6.70. The firm has a market capitalization of $2.28 billion, a P/E ratio of 6.35 and a beta of 0.42. Bausch Health Cos has a 1 year low of $4.25 and a 1 year high of $8.69.

Hedge Funds Weigh In On Bausch Health Cos

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. increased its position in shares of Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos in the 1st quarter worth $68,000. Schonfeld Strategic Advisors LLC purchased a new position in Bausch Health Cos in the 3rd quarter worth about $95,000. Finally, Aquatic Capital Management LLC bought a new stake in shares of Bausch Health Cos in the third quarter worth approximately $100,000. 78.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BHC has been the topic of a number of recent analyst reports. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Barclays assumed coverage on shares of Bausch Health Cos in a report on Monday, December 8th. They issued an “equal weight” rating and a $8.00 target price on the stock. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Truist Financial increased their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Five research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.67.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.